GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Financial Strength

West Pharmaceutical Services (West Pharmaceutical Services) Financial Strength : 9 (As of Mar. 2024)


View and export this data going back to 1980. Start your Free Trial

What is West Pharmaceutical Services Financial Strength?

West Pharmaceutical Services has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

West Pharmaceutical Services Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

West Pharmaceutical Services's Interest Coverage for the quarter that ended in Mar. 2024 was 78.69. West Pharmaceutical Services's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.11. As of today, West Pharmaceutical Services's Altman Z-Score is 20.03.


Competitive Comparison of West Pharmaceutical Services's Financial Strength

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


West Pharmaceutical Services's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Financial Strength distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Financial Strength falls into.



West Pharmaceutical Services Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

West Pharmaceutical Services's Interest Expense for the months ended in Mar. 2024 was $-2 Mil. Its Operating Income for the months ended in Mar. 2024 was $126 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $155 Mil.

West Pharmaceutical Services's Interest Coverage for the quarter that ended in Mar. 2024 is

Interest Coverage=-1*Operating Income (Q: Mar. 2024 )/Interest Expense (Q: Mar. 2024 )
=-1*125.9/-1.6
=78.69

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. West Pharmaceutical Services Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

West Pharmaceutical Services's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(151.4 + 155.2) / 2781.6
=0.11

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

West Pharmaceutical Services has a Z-score of 20.03, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 20.03 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


West Pharmaceutical Services  (NYSE:WST) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

West Pharmaceutical Services has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.


West Pharmaceutical Services Financial Strength Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


West Pharmaceutical Services (West Pharmaceutical Services) Business Description

Traded in Other Exchanges
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-0645
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.
Executives
Chad Winters officer: VP, CAO & Controller 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Charles Witherspoon officer: VP & Treasurer 530 HERMAN O WEST DRIVE, EXTON PA 19341
Annette F Favorite officer: Sr. VP Human Resources Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark officer: Senior Vice President 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai officer: VP Corp Development & Strategy 530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Silji Abraham officer: Chief Digital & Trans Officer 5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Eric Mark Green officer: Chief Executive Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Bernard Birkett officer: Sr VP, CFO & Treasurer 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Thomas W Hofmann director FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Stephen H Lockhart director C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph director 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay officer: SVP, GC & Corporate Secretary 530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller officer: Sr. VP, GC & Corp. Sec. 530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo officer: SVP, Glob Ops and Supply Chain 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel director 940 WINTER STREET, WALTHAM MA 02451